


**Product Name** : SWTX-143  
**Cat. No.** : PC-21317  
**CAS No.** : 2766575-48-6  
**Molecular Formula** : C<sub>19</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>O  
**Molecular Weight** : 361.37  
**Target** : YAP-TEAD  
**Solubility** : 10 mM in DMSO



CAS: 2766575-48-6

## Biological Activity

SWTX-143 is a potent, irreversible and covalent **YAP/TAZ-TEAD** inhibitor with IC<sub>50</sub> of 12 nM in luciferase reporter assays, binds to the palmitoylation pocket of all four TEAD isoforms, inhibits Hippo pathway-mutant cancer cells.

SWTX-143 potently represses luciferase expression from the TEAD reporter (IC<sub>50</sub>=12 nmol/L) while not affecting the viability of HEK293 cells.

SWTX-143 is sufficient to evoke a long-lasting transcriptional impact.

SWTX-143 inhibits the proliferation of Hippo pathway-mutant cancer cell lines with IC<sub>50</sub> of 5-207 nM against three distinct desmethyloma cancer cell lines that are characterized by and depend on loss-of-function alterations in NF2 (Mero-14, NCI-H226, and CI-H2052) and one that is deficient in ATS1 and LATS2 (MSTO-211H).

SWTX-143 only modestly impacts the proliferation of the NCI-H28 and NCI-H2452 mesothelioma, HeLa, SiHa, and CaSki cancer cell lines which lack genetic alterations in known Hippo pathway components (Hippo-WT).

SWTX-143 (10, 25, and 50 mg/kg) causes regression of NF2-deficient human mesothelioma xenografts.

SWTX-143 also selectively impairs the growth of NF2-mutant kidney cancer cell lines, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models.

## References

Hanne Hillen, et al. *Mol Cancer Ther.* 2023 Sep 23. doi: 10.1158/1535-7163.MCT-22-0681.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com